Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment.Journal of hepatocellular carcinoma · 2023
   Article
2. Identification of a Novel Prognostic Signature Based on N-Linked Glycosylation and Its Correlation with Immunotherapy Response in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023
   Article
3. Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy.Molecular therapy oncolytics · 2022
   Article
4. Integrative analyses of prognosis, tumor immunity, and ceRNA network of the ferroptosis-associated gene FANCD2 in hepatocellular carcinoma.Frontiers in genetics · 2022
   Article
5. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.Expert opinion on therapeutic targets · 2021
   Review
6. IFN-α facilitates the effect of sorafenib via shifting the M2-like polarization of TAM in hepatocellular carcinoma.American journal of translational research · 2021
   Article
7. Annexin A2 promotion of hepatocellular carcinoma tumorigenesisWorld journal of gastroenterology · 2020
   Review
8. Metabolism-associated molecular classification of hepatocellular carcinoma.Molecular oncology · 2020
   Article
9. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions.Journal of cellular physiology · 2019
   Review
10. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.Disease markers · 2019
    Article
11. The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy.Journal of Cancer · 2018
    Article
12. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2017
    Review
13. Hepatocellular Carcinoma Genetic Classification.Cancer journal (Sudbury, Mass.)
    Article

Corrections and comments

• Comment on
  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as